These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20959963)

  • 1. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study.
    Sambrook PN; Cameron ID; Chen JS; March LM; Simpson JM; Cumming RG; Seibel MJ
    Osteoporos Int; 2011 Sep; 22(9):2551-6. PubMed ID: 20959963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bisphosphonates are associated with reduced mortality after hip fracture.
    Beaupre LA; Morrish DW; Hanley DA; Maksymowych WP; Bell NR; Juby AG; Majumdar SR
    Osteoporos Int; 2011 Mar; 22(3):983-91. PubMed ID: 21052642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Bisphosphonates on Fracture Outcomes Among Frail Older Adults.
    Zullo AR; Zhang T; Lee Y; McConeghy KW; Daiello LA; Kiel DP; Mor V; Berry SD
    J Am Geriatr Soc; 2019 Apr; 67(4):768-776. PubMed ID: 30575958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study.
    Cameron ID; Chen JS; March LM; Simpson JM; Cumming RG; Seibel MJ; Sambrook PN
    J Bone Miner Res; 2010 Apr; 25(4):866-72. PubMed ID: 19839771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between timing of zoledronic acid infusion and hip fracture healing.
    Colón-Emeric C; Nordsletten L; Olson S; Major N; Boonen S; Haentjens P; Mesenbrink P; Magaziner J; Adachi J; Lyles KW; Hyldstrup L; Bucci-Rechtweg C; Recknor C;
    Osteoporos Int; 2011 Aug; 22(8):2329-36. PubMed ID: 21153021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial.
    Greenspan SL; Perera S; Ferchak MA; Nace DA; Resnick NM
    JAMA Intern Med; 2015 Jun; 175(6):913-21. PubMed ID: 25867538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
    Colón-Emeric CS; Mesenbrink P; Lyles KW; Pieper CF; Boonen S; Delmas P; Eriksen EF; Magaziner J
    J Bone Miner Res; 2010 Jan; 25(1):91-7. PubMed ID: 19580467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-yearly zoledronic acid in hip fracture prevention.
    Demontiero O; Duque G
    Clin Interv Aging; 2009; 4():153-64. PubMed ID: 19503777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Zoledronic acid reduces risk of any new clinical fracture and risk of death after surgical repair of a low-trauma hip fracture].
    Leszczyński P
    Chir Narzadow Ruchu Ortop Pol; 2010; 75(3):168-71. PubMed ID: 21038635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
    Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
    Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
    N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
    Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
    Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
    Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
    Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
    J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates and mortality: confounding in observational studies?
    Bergman J; Nordström A; Hommel A; Kivipelto M; Nordström P
    Osteoporos Int; 2019 Oct; 30(10):1973-1982. PubMed ID: 31367949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hip fractures in users of first- vs. second-generation bisphosphonates.
    Mamdani M; Kopp A; Hawker G
    Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data.
    Miller PD
    Curr Med Res Opin; 2008 Jan; 24(1):107-19. PubMed ID: 18031594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.